Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients

Inclusion criteria

• Age greater than or equal to 18 years of age
• Karnofsky Performance Status of greater than or equal to 60
• FIGO Surgical Stage I, II, and III
• Pathologic confirmation of endometrial cancer
• Patient status post hysterectomy
• Patients with local or regional metastases are eligible for this protocol, but not those with distant metastases
• Patients must have adequate:

• Bone Marrow Function:

• ANC ≥ 1,500/mcl (< CTCAE v 3.0 Grade 1).
• Platelets ≥ 100,000/mcl (< CTCAE v3.0 Grade 1).
• Renal Function:

• Serum creatinine ≤ institutional upper limit normal (ULN) (CTCAE v 3.0 Grade 0). Note: if serum creatinine > ULN, a 24-hour creatinine clearance must be collected and must be > 50 mL/min.
• Hepatic Function:

• Bilirubin ≤ 1.5 x ULN (< CTCAE v 3.0 Grade 1).
• SGOT≤ 2.5 x ULN (< CTCAE v 3.0 Grade 1).
• Alkaline phosphatase ≤ 2.5 x ULN (< CTCAE v 3.0 Grade 1).
• Neurologic Function:

• Neuropathy (sensory and motor) < CTCAE v 3.0 Grade 1.

Exclusion criteria

• Age less than 18 years of age
• Karnofsky Performance Status less than 60
• Radiographic or pathologic evidence of metastatic disease (other than pelvic or para-aortic lymph nodes)
• Prior pelvic radiation therapy